Seeking Alpha

Regulus Therapeutics enters into a strategic alliance with AstraZeneca (AZN) to discover,...

Regulus Therapeutics enters into a strategic alliance with AstraZeneca (AZN) to discover, develop, and commercialize microRNA therapeutics for three exclusive targets currently in pre-clinical development. The targets focus on cardiovascular and metabolic diseases and oncology. Under the terms of the agreement, AZN will make an equity investment and an upfront payment to Regulus. AZN +0.3% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs